U.S. Markets open in 7 hrs 6 mins

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.000.00 (0.00%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.00
Open13.00
Bid0.00 x 800
Ask0.00 x 2200
Day's Range12.39 - 13.18
52 Week Range12.10 - 19.51
Volume189,570
Avg. Volume597,530
Market Cap738.729M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bioventus to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 25, 2021
    GlobeNewswire

    Bioventus to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 25, 2021

    DURHAM, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that fourth quarter and fiscal year 2020 financial results will be released after the market closes on Thursday, March 25, 2021. Management will host a conference call to discuss its financial results and provide a business update, with a question and answer session, at 5:00 p.m. Eastern Time on March 25, 2021. Those who would like to participate may dial 844-945-2085 (442-268-1266 for international callers) and provide access code 2158468. A live webcast of the call and any accompanying materials will also be provided on the investor relations section of the Company's website at https://ir.bioventus.com/. The webcast will be archived on the Company’s website at https://ir.bioventus.com/ and available for replay until March 25, 2022. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. CONTACT: Media Contact: Thomas Hill 919-474-6715 thomas.hill@bioventusglobal.com Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke/ICR Investor.relations@bioventus.com

  • Barrons.com

    Signify Health, Apria, Bioventus, and LoanDepot Make Their Market Debuts

    Signify Health, Apria, Bioventus, and loanDepot began trading Thursday. LoanDepot jumped nearly 57%.

  • Bioventus Announces Pricing of Initial Public Offering
    GlobeNewswire

    Bioventus Announces Pricing of Initial Public Offering

    DURHAM, N.C., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $13.00 per share. The Company’s Class A common stock is expected to begin trading on the Nasdaq Global Select Market under the symbol “BVS”, and the offering is expected to close on February 16, 2021, subject to customary closing conditions. The underwriters have also been granted a 30-day option to purchase up to 1,200,000 additional shares of Class A common stock from Bioventus at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $104.0 million (or $119.6 million if the underwriters exercise their option to purchase additional shares in full). Morgan Stanley, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are serving as joint lead book-running managers and as representatives of the underwriters for the proposed offering. Canaccord Genuity LLC is acting as lead manager for the offering. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the proposed offering may be obtained from any of the following sources: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com;J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; orGoldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission ("SEC") on February 10, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Bioventus Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. SOURCE: Bioventus Inc. Contacts:InvestorsBioventus Investor RelationsInvestor.relations@bioventus.com Media Thomas Hillthomas.hill@bioventusglobal.com